Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …

The discovery of an identical mutation (V617F) of the JAK2 gene in patients with
polycythemia vera, essential thrombocythemia, and myelofibrosis—the principal …

Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by
aberrant hematopoietic proliferation and an increased tendency toward leukemic …

Effective targeted cancer therapeutic development depends upon distinguishing disease-
associated 'driver'mutations, which have causative roles in malignancy pathogenesis, from …

Abstract Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-
1β has been implicated in various pathological conditions including myeloproliferative …

Background The myelodysplastic syndromes and myeloproliferative disorders are
associated with deregulated production of myeloid cells. The mechanisms underlying these …

Background The V617F mutation, which causes the substitution of phenylalanine for valine
at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with …

Recently, a gain-of-function MPL mutation, MPL W515L, was described in patients with
JAK2 V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more …

High platelet counts in essential thrombocythemia (ET) can be effectively lowered by
treatment with either anagrelide or hydroxyurea. In 259 previously untreated, high-risk …

Abstract Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …